Antiviral Long Acting Drugs Landing in People Living With HIV

Inclusion Criteria: * People living with HIV-1 infection that could, according to clinical practice, switch current ART to IM CAB + RPV; * Aged 18 years or older at the time of signing the informed consent. * People willing to switch to long-acting therapy * on a stable (≥6 months) antiretroviral regimen and virologically suppressed (HIV-1 RNA \<50 copies/ml): * Documented evidence of plasma HIV-1 RNA measurements \<50 c/mL in the 6 months prior to Screening. * Plasma HIV-1 RNA \<50 c/mL at Screening. * Ability to understand informed consent form and other relevant regulatory documents. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: * Within 6 months prior to Screening, any plasma HIV-1 RNA measurement \>=50 c/mL or within the 6 to 12-month window prior to Screening, any plasma HIV-1 RNA measurement \>200 c/mL, or 2 or more plasma HIV-1 RNA measurements \>=50 c/mL. * Present or past evidence of viral resistance to agents of the NNRTI or INI class or prior treatment failure with agents of NNRTI or INSTI class * Unwillingness or any condition that might prevent the completion of all surveys over study follow-up. * Any contraindication for CAB LA, RPV LA, oral Cabotegravir or Rilpivirine (see EU SmPC): * Women who are pregnant, breastfeeding or plan to become pregnant or breastfeed during the study * Any evidence of a current Center for Disease Control and Prevention (CDC) Stage 3 disease…